Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals Restructures Debt: Oramed Pharmaceuticals has entered into agreements with Scilex Holding Company to restructure $22.5 million of its Senior Secured Promissory Note, receiving $25 million in new convertible notes and warrants for shares, while also acquiring an 8% royalty on certain Scilex products.
CEO's Statement on Investment Value: CEO Nadav Kidron expressed optimism about the restructuring, highlighting potential value enhancement through conversion options and warrants, as well as a stake in the growth of Scilex's product ZTlido, aligning with Oramed's strategy to maximize shareholder value.
Trade with 70% Backtested Accuracy
Analyst Views on ORMP
About ORMP
About the author
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend
- Significant Investment Returns: Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, bringing total returns on its $99.5 million investment to $118 million, demonstrating the company's success in investment management and profitability.
- Debt Structure Optimization: Oramed retains a $27 million note and a $12 million convertible note, which can be converted into Scilex equity at $36 per share, ensuring potential capital appreciation in the future.
- Shareholder Reward Plan: The company's board approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, aimed at rewarding shareholders and enhancing investor confidence.
- Funding Source Assurance: This dividend will be funded with surplus capital, reflecting Oramed's financial management robustness and confidence in future investments.
ORAMED PHARMACEUTICALS INC. ANNOUNCES DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS AS DIVIDEND
Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.
Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.
Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.
Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.
Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.
Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.
Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.
Oramed Shares Update with Shareholders on Oral Insulin Program Progress, Notable Investment Gains, and Future Growth Plans
Oral Insulin Program Update: Oramed Pharmaceuticals is advancing its oral insulin program independently, launching a new U.S. trial to validate its formulation based on promising results from identified high-responder subgroups.
Investment Portfolio Performance: The company has strategically invested in various biomedical firms, achieving significant returns, including a $99.5 million loan to Scilex and investments in Alpha Tau and BioXcel, which have shown substantial gains.
Shareholder Commitment: Oramed reaffirms its commitment to rewarding shareholders, including plans for a one-time dividend, despite the termination of a joint venture that would have facilitated this.
Growth Strategy and Financial Health: The company reports a growth in total cash and assets to approximately $210 million, highlighting its ability to create value through strategic capital deployment and a diversified investment approach.
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Strategic Investment Announcement: Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, purchasing approximately 14.1 million shares to support the development of Alpha Tau's innovative cancer therapy technology, Alpha DaRT.
Collaboration Goals: The partnership aims to leverage Oramed's expertise in capital markets and business strategy to accelerate Alpha Tau's clinical trials, manufacturing expansion, and commercialization efforts, while also enhancing governance through board appointments.
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend
- Significant Investment Returns: Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, bringing total returns on its $99.5 million investment to $118 million, demonstrating the company's success in investment management and profitability.
- Debt Structure Optimization: Oramed retains a $27 million note and a $12 million convertible note, which can be converted into Scilex equity at $36 per share, ensuring potential capital appreciation in the future.
- Shareholder Reward Plan: The company's board approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, aimed at rewarding shareholders and enhancing investor confidence.
- Funding Source Assurance: This dividend will be funded with surplus capital, reflecting Oramed's financial management robustness and confidence in future investments.
ORAMED PHARMACEUTICALS INC. ANNOUNCES DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS AS DIVIDEND
Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.
Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.
Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.
Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.
Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.
Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.
Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.
Oramed Shares Update with Shareholders on Oral Insulin Program Progress, Notable Investment Gains, and Future Growth Plans
Oral Insulin Program Update: Oramed Pharmaceuticals is advancing its oral insulin program independently, launching a new U.S. trial to validate its formulation based on promising results from identified high-responder subgroups.
Investment Portfolio Performance: The company has strategically invested in various biomedical firms, achieving significant returns, including a $99.5 million loan to Scilex and investments in Alpha Tau and BioXcel, which have shown substantial gains.
Shareholder Commitment: Oramed reaffirms its commitment to rewarding shareholders, including plans for a one-time dividend, despite the termination of a joint venture that would have facilitated this.
Growth Strategy and Financial Health: The company reports a growth in total cash and assets to approximately $210 million, highlighting its ability to create value through strategic capital deployment and a diversified investment approach.
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Strategic Investment Announcement: Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, purchasing approximately 14.1 million shares to support the development of Alpha Tau's innovative cancer therapy technology, Alpha DaRT.
Collaboration Goals: The partnership aims to leverage Oramed's expertise in capital markets and business strategy to accelerate Alpha Tau's clinical trials, manufacturing expansion, and commercialization efforts, while also enhancing governance through board appointments.
